Preoperative statins and infectious complications following cardiac surgery

Current Medical Research and Opinion

Volumn 23, Issue 8, 2007, Pages 1783-1790

  Coleman, Craig I ^a,b   Lucek, Diana M ^a,b   Hammond, Jonathan ^a   White, C Michael ^a,b  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Cardiac surgery; Infection; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; STEROID;

ADULT; AGED; ARTICLE; BACTEREMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; FEMALE; HEART SURGERY; HUMAN; HYPERCHOLESTEROLEMIA; LEG VEIN HARVEST SITE INFECTION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; POSTOPERATIVE INFECTION; PREOPERATIVE CARE; SMOKING; TRACHEOTOMY SITE INFECTION; URINARY TRACT INFECTION; WOUND;

AGED; COHORT STUDIES; CORONARY ARTERY BYPASS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; INFECTION; MALE; MIDDLE AGED; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 34548130730     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X210570     Document Type: Article

References (19)

1. Fowler VG, O'Brien SM, Muhlbaier LH, et al. Clinical predictors of major infections after cardiac surgery. Circulation 2005;112[Suppl I]:358i-65i
2. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology Web Site. Available at: http://www.acc.org/clinical/guidelines/cabg/cabg.pdf
3. Catron DM, Lange Y, Borensztajn J, et al. Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation. Infect Immunity 2004;72:1036-42
4. Kothe H, Dalhoff K, Rupp J, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000;10:1760-3
5. Liappis AP, Kan VL, Rochester CG, et al. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001;33:1352-7
6. Thomsen RW, Hundborg HH, Johnsen SP, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006;34:1080-6
7. Mortensen EM, Restrepo MI, Anzueto A, et al. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Resp Res 2005;6:82 Online. doi:10.1186/1465-9921-6-82
8. Van de Garde EMW, Souverein PC, Hoss AW, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006;11:957-61
9. Ali IS, Buth KJ. Impact of preoperative statin use on sepsis and deep sternal wound infection following cardiac surgery. Circulation 2005;111:e320
10. Society of Thoracic Surgeons (STS) national database. STS adult cardiac database - definitions of terms. Available at: www.sts.org/doc/8428 (accessed 11/8/2006)
11. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004;110:880-5
12. Hackman DG, Mamandi M, Redelmeir DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006;367:413-18
13. Catron DM, Lange Y, Borensztajn J, et al. Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation. Infect Immunity 2004;72:1036-42
14. Ray KK, Cannon CP. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Curr Opin Lipidol 2004;15:637-43
15. White CM. HMg CoA Reductase inhibitor-induced muscle toxicity: risks, monitoring, and management. Formulary 2002;37:588-93
16. Masters BA, Palmoski MJ, Flint O, et al. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 1995;131:163-74
17. Del Real G, Jiminez-Baranda S, Mira S, et al. Statins inhibit HIV-1 infection by downregulating Rho activity. J Exp Med 2004;200:541-7
18. Giguere JF, Tremblay MJ. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 2004;78:12062-5
19. Potena L, Frascaroli G, Grigioni F, et al. Hydroxymethyl-glutaryl coenzyme A reductase inhibition limits cytomegalovirus infection in human endothelial cells. Circulation 2004;109:532-6